Related Experiment Video
Updated: Sep 19, 2025
Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
Published on: March 6, 2018
Transurethral holmium laser enucleation of prostate shows remarkable efficacy in treating benign prostatic
Feng-Rong He1, Guo-Deng Jian1, Ri-Zhao Tan1
1Department of Urology, Foshan Fosun Chancheng Hospital Foshan 528011, Guangdong, China.
Objective:
To evaluate the effects of transurethral holmium laser enucleation of the prostate (HoLEP) in treating benign prostatic hyperplasia (BPH).
Methods:
This retrospective study included 100 BPH patients who visited Foshan Fosun Chancheng Hospital from January 2022 to June 2023. Patients were divided into two groups: 50 treated with transurethral resection of the prostate (control group) and 50 with transurethral HoLEP (observation group). We compared clinical efficacy, surgical parameters, maximum urinary flow rate (Qmax), post-void residual volume (PRV), prostate-specific antigen (PSA), hemoglobin (Hb), interleukin-6 (IL-6), C-reactive protein (CRP), International Prostate Symptom Score (IPSS), quality of life (QOL), and complication rates.
Results:
The observation group showed significantly reduced operative time, blood loss, catheterization duration, and hospitalization compared to the control group (all P<0.05). Postoperatively, Qmax was higher and PRV lower in the observation group (both P<0.05). PSA was lower, and Hb was higher in the observation group than those in the control group (both P<0.05). Both IL-6 and CRP levels increased post-surgery, but were significantly lower in the observation group (both P<0.05). The observation group also had better IPSS and QOL scores and a lower complication rate (16% vs. 56%, all P<0.05).
Conclusion:
HoLEP is an effective treatment for BPH, offering advantages such as reduced surgical time, lower complication rates, improved urodynamics, and better patient outcomes in terms of symptoms and quality of life.
